VBL Therapeutics (VBLT) Tops Q3 EPS by 3c

November 10, 2016 7:06 AM EST
Get Alerts VBLT Hot Sheet
Trade VBLT Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

VBL Therapeutics (NASDAQ: VBLT) reported Q3 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15).

At September 30, 2016, the Company had cash, cash equivalents and short-term bank deposits totaling $48.9 million and working capital of $46.0 million. We expect that our cash, cash equivalents and short-term bank deposits will enable us to fund our operating expenses and capital expenditure requirements into 2019. Our cash position is expected to be sufficient for completion of our on-going Phase 3 clinical trial of VB-111 in rGBM, for a potential registration trial of VB-111 in ovarian cancer and to support the investment in the new Modiin facility.

For earnings history and earnings-related data on VBL Therapeutics (VBLT) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment